IPNEU22061 / DAY101-002 / Korones
Basic Study Information
Purpose:
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate
the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care
(SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an
activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line
systemic therapy.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
David Korones
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search